Rodger D. MacArthur, MD

The newly published START trial conclusively demonstrates advantages of initiating antiretroviral therapy as soon as an HIV-infected person enters care.

CROI offers more than 1100 high-quality presentations and myriad poster sessions. You have so little time. Our CROI blogger offers 6 different ways to maximize learning at any jam-packed meeting, depending on your personal style.

The antiviral future holds great promise for people living with HIV: better-tolerated, less toxic, drugs are about to come to market, and we are about to see the introduction of drugs from 1 or 2 new classes.

Here is compelling reason why every MD needs to test his or her patients for HCV, and get them into therapy as soon as possible.

Here’s a look at how emergency room experiences affect linkage to care and retention in care among patients with HIV.

Here: an update on progress and challenges in HIV eradication, and a focus on the efforts of the President’s Emergency Plan for AIDS Relief.

Is pre-exposure prophylaxis an effective means of reducing the number of new HIV infections?

Do we, in resource-rich countries, have the will and the resources to spend on HIV or HCV eradication? We have the tools (medications), but the goal of eradicating both infections seems as elusive as ever.

Useful details here about HIV and age-related issues, sexual dysfunction, heart disease, and end-organ damage.

These suggestions will enhance your enjoyment of long meetings and will have your colleagues remarking on what a jolly, friendly person you really are. Ignore the advice at your own peril.

The good: this premier HIV conference offers a banquet of exceptional material. The bad: the expense and the grind of covering a meeting this rich-and lengthy.

Two studies demonstrate that raltegravir is an extremely well-tolerated and potent component of a combination antiretroviral regimen.

“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.

It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.

The START trial is likely to provide a definitive answer to one of the most important clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.

Stark defunding for AIDS research may lead to increased pharmaceutical influence, less population diversity in research, and dwindling new HIV-specific advances.

First of all, it is important to know what exactly is meant by “the best.”

HIV infection had ravaged Amber's immune system, but not her spirit. Here, her story told by the physician who continues to walk with her.

Coinfection with HIV and HCV presents a problem: many of the drugs used routinely to treat HIV have adverse interactions with the newer, and older, treatments for HCV.

Women tend to be excluded from pharmaceutical company-sponsored trials of antiretroviral medications.

To suggest today that condoms are “obsolete” sounds heretical and like a topic ripe for heated debate. Here, HIV/AIDS blogger Dr Rodger MacArthur lays out the science for your review.

One theory behind a functional cure for HIV infection is based on early, intensive treatment with combined antiretroviral therapy.

Approximately 25% of those infected with HIV are unaware of their positive status. The USPSTF says universal screening can help reduce disease burden.

What are some of the more common side effects of antiretroviral therapy, and what can the primary care physician do to help manage these effects? In this podcast, infectious disease expert Rodger MacArthur, MD, offers insights and points readers to updated comprehensive guidelines.